Summary Presentation based on healthcare white paper by grail research
•
1 like•660 views
A presentation prepared by me, summarizing a healthcare white paper published by Grail Research on their website.
Report
Share
Report
Share
Recommended
GetPersonalized! Pharma's perspective on the future, Claudia Karnbach
Pharma's perspective on the future, Claudia Karnbach, Head, Global Business Development and Licensing, Specialty Medicine, Bayer Healthcare Pharmaceuticals (USA, New York)
Case for emerging 9 sustaining oncology innovation
The document discusses the challenges facing major oncology innovator companies as their traditional cash cow drugs lose market share to biosimilars. It argues that innovators need to look beyond traditional Western markets and consider partnering with emerging markets like India to strengthen their healthcare systems and generate sustainable revenues. This could help build new cash cows to fund future innovation while improving access in populations with high cancer rates. The document outlines how an integrated approach with partners across government, non-profits and hospitals could work to mutually benefit patients, innovators and healthcare systems in emerging markets.
Amcham Physician Jan15
Physicians in China are increasingly reluctant to meet with pharmaceutical sales representatives due to government investigations into bribery. Major pharmaceutical companies are changing their sales models in response, such as ending payments to physicians for speaking or conference participation. These changes may significantly impact sales volumes for some companies. The Chinese government is also transforming the healthcare system through expanded coverage, improved quality, and increased efficiency, which presents challenges and opportunities for pharmaceutical companies to adapt their strategies.
Warren Granger
The medical technology industry faces three fundamental challenges according to the document.
1) Sustaining innovation is challenged by increased regulatory hurdles, capital constraints, and pricing pressures at every stage from idea to commercialization.
2) Delivering value and outcomes is increasingly important as purchasing decisions consolidate, comparative effectiveness research rises, and higher bars are set to bring products to market.
3) Fueling growth requires diversifying products, geographies, and offers including emphasizing outcomes, lower-cost emerging market products, and managing spending jointly with hospitals and insurers.
Insight_Medtech
The document discusses four key concepts for medical device executives to understand in order to succeed in China's rapidly growing medical devices market. First, executives must seize China's market opportunities as the market is expected to reach $50 billion by 2017. Second, they must understand the Chinese government's important role in regulating the industry and procurement processes. Third, executives should monitor healthcare reforms that could impact market access. Fourth, local competition is growing, so companies must balance global and local strategies to stay competitive. The medical devices market in China offers great potential for growth but also complexity that executives must navigate carefully.
C:\Whitney Docs\Healthreformandkeyhealthindustries
This document summarizes the opportunities, challenges, and implications for key health industries under the Affordable Care Act, including hospitals, health insurers, physicians, pharmaceutical companies, and medical device manufacturers. It notes that while coverage expansions create new opportunities for revenue growth, these industries will also face pressure on profits from payment cuts, new taxes and fees, tighter regulation, and a shift toward public program reimbursement. Overall the industries will need to adapt to new delivery system and payment reforms that emphasize quality and value over volume.
Redx Pharma - Neil Murray
The document discusses challenges facing the traditional drug discovery model and opportunities for a new model. The traditional model of big pharma downsizing R&D and biotechs being dependent on venture capital is seen as inefficient. Academia also lacks funding for translational research. However, times may be changing as large pharma forms more collaborations and invests in innovative models like Redx Pharma, which uses science, expertise, and non-dilutive funding to build an early pipeline of assets for partners and achieve sustainability. Quotes from Keynes, Hayek, and an Lilly executive provide perspectives on economic theories and the need for industry evolution to improve patient access.
Responses Of Pharma To Changing Climate
Provide an update on the current challenges that the pharma industry is facing, and some of the changes that are predicted to occur as a result. Also provide insights on how to build a career in the pharmaceutical industry by embracing the changing environment. Focus on Canadian statistics in some slides.
Recommended
GetPersonalized! Pharma's perspective on the future, Claudia Karnbach
Pharma's perspective on the future, Claudia Karnbach, Head, Global Business Development and Licensing, Specialty Medicine, Bayer Healthcare Pharmaceuticals (USA, New York)
Case for emerging 9 sustaining oncology innovation
The document discusses the challenges facing major oncology innovator companies as their traditional cash cow drugs lose market share to biosimilars. It argues that innovators need to look beyond traditional Western markets and consider partnering with emerging markets like India to strengthen their healthcare systems and generate sustainable revenues. This could help build new cash cows to fund future innovation while improving access in populations with high cancer rates. The document outlines how an integrated approach with partners across government, non-profits and hospitals could work to mutually benefit patients, innovators and healthcare systems in emerging markets.
Amcham Physician Jan15
Physicians in China are increasingly reluctant to meet with pharmaceutical sales representatives due to government investigations into bribery. Major pharmaceutical companies are changing their sales models in response, such as ending payments to physicians for speaking or conference participation. These changes may significantly impact sales volumes for some companies. The Chinese government is also transforming the healthcare system through expanded coverage, improved quality, and increased efficiency, which presents challenges and opportunities for pharmaceutical companies to adapt their strategies.
Warren Granger
The medical technology industry faces three fundamental challenges according to the document.
1) Sustaining innovation is challenged by increased regulatory hurdles, capital constraints, and pricing pressures at every stage from idea to commercialization.
2) Delivering value and outcomes is increasingly important as purchasing decisions consolidate, comparative effectiveness research rises, and higher bars are set to bring products to market.
3) Fueling growth requires diversifying products, geographies, and offers including emphasizing outcomes, lower-cost emerging market products, and managing spending jointly with hospitals and insurers.
Insight_Medtech
The document discusses four key concepts for medical device executives to understand in order to succeed in China's rapidly growing medical devices market. First, executives must seize China's market opportunities as the market is expected to reach $50 billion by 2017. Second, they must understand the Chinese government's important role in regulating the industry and procurement processes. Third, executives should monitor healthcare reforms that could impact market access. Fourth, local competition is growing, so companies must balance global and local strategies to stay competitive. The medical devices market in China offers great potential for growth but also complexity that executives must navigate carefully.
C:\Whitney Docs\Healthreformandkeyhealthindustries
This document summarizes the opportunities, challenges, and implications for key health industries under the Affordable Care Act, including hospitals, health insurers, physicians, pharmaceutical companies, and medical device manufacturers. It notes that while coverage expansions create new opportunities for revenue growth, these industries will also face pressure on profits from payment cuts, new taxes and fees, tighter regulation, and a shift toward public program reimbursement. Overall the industries will need to adapt to new delivery system and payment reforms that emphasize quality and value over volume.
Redx Pharma - Neil Murray
The document discusses challenges facing the traditional drug discovery model and opportunities for a new model. The traditional model of big pharma downsizing R&D and biotechs being dependent on venture capital is seen as inefficient. Academia also lacks funding for translational research. However, times may be changing as large pharma forms more collaborations and invests in innovative models like Redx Pharma, which uses science, expertise, and non-dilutive funding to build an early pipeline of assets for partners and achieve sustainability. Quotes from Keynes, Hayek, and an Lilly executive provide perspectives on economic theories and the need for industry evolution to improve patient access.
Responses Of Pharma To Changing Climate
Provide an update on the current challenges that the pharma industry is facing, and some of the changes that are predicted to occur as a result. Also provide insights on how to build a career in the pharmaceutical industry by embracing the changing environment. Focus on Canadian statistics in some slides.
Pharma Co's in Emerging Markets - Innovation & Technology are Key to Growth
Emerging markets are predicted to account for a third of global pharmaceutical spend by the end of next year – and seen as critical for the sustained growth of leading pharma companies.
The report summarises the findings of a Cambridge Consultants workshop held in Mumbai, India, earlier this year. The product design and development firm brought together senior personnel from both Indian and multinational pharma companies to debate whether emerging markets can be an opportunity to drive sustainable growth.
The consensus was that the term ‘emerging markets’ covers nations in parts of Africa, the Middle East and South East Asia, as well as the more traditional countries of Brazil, Russia, India and China. But all the delegates said emerging markets cannot be grouped into a single cluster to chalk out common strategies. Clustering markets around parameters such as regulatory pathways or therapeutic applications was considered the best approach.
“Emerging markets are facing rapid growth of chronic ‘Western’ diseases like diabetes, hypertension, chronic respiratory problems, cancer, heart disease and neurological disorders,” said Ambuj Jain, India general manager at Cambridge Consultants. “In some cases, conditions like diabetes are turning into near-epidemic situations.
“In India, for example, the prevalence of diabetes and cancer is projected to rise by 25-40% over the next 10 years. This shift gives pharma companies an opportunity to market their global products in emerging markets, backed by tested ‘go-to-market’ strategies and operating models.”
The report says key barriers which need to be addressed in many emerging markets are the affordability and accessibility of medicines. Improvements in affordability will be driven by rising disposable incomes and increasing insurance coverage. Growth in accessibility will come from increases in government spending and medical infrastructure, and new business models for rural areas. The acceptability of medicines is also expected to rise, as a result of the growth in chronic conditions – and the resulting increase in the self-administration of drugs.
Workshop delegate Sanjay Bhanushali, a director of global pharma company Cipla, said: “Emerging markets are critical for the sustained growth of leading pharmaceutical organisations. They represent a significant proportion of the world’s population and many of their governments are increasingly focusing on improving healthcare. Innovation and technology – with the emphasis on patient and stakeholder needs – will be crucial to success in these markets.”
Diagnostics was seen by the workshop delegates as a key focus area where innovation can drive sustained growth.
Pharma trends in bric economies
This document discusses trends in emerging pharmaceutical markets, focusing on Brazil, Russia, India, and China. It provides an overview of the current healthcare systems and pharmaceutical markets in each country. Some key points discussed include growth patterns in developed markets flattening while emerging markets see significant growth potential. The document also outlines future trends in each country such as increasing regulation, emphasis on generics, and strategies pharmaceutical companies can employ to succeed in these emerging markets.
Medical devices equipped for the future
The document discusses disruptive changes underway in the medical devices industry that will transform it over the next 5 years. It identifies 5 major disruptors: 1) a power shift to payers and providers who are focusing more on cost and value-based evidence, 2) heightened regulatory scrutiny that is increasing compliance costs, 3) unclear sources of innovation as R&D spending yields diminishing returns, 4) new healthcare delivery models that are shifting care settings out of hospitals, and 5) a need to serve lower socioeconomic classes in developing markets. The disruptors threaten $34 billion in industry profits by 2020 but taking appropriate measures could help maintain revenue growth and offset margin declines, preserving significant value for medical device companies.
Learn How to Beat Problems Feb23, 2007
The document discusses the Bulgarian pharmaceutical market and opportunities for growth. It notes that Bulgaria provides political and economic stability with low costs and 5.5% annual growth. The pharmaceutical industry is moving towards generics and partnerships to lower costs and access international markets. It introduces Tchaikapharma as part of the vertically integrated CL BioPharma Group, which provides manufacturing, distribution, and clinical services to help companies access the Bulgarian market and beyond.
2015 Medical Device Outlook - Deloitte
United States life sciences companies face numerous challenges in 2015 related to market changes, consolidation, pricing pressures, and health reform. Six key issues are highlighted: 1) Market reconfiguration and consolidation due to factors like expiring patents are driving the need for companies to reassess strategies and explore M&A opportunities. 2) Pricing pressures exist from government efforts to control costs and from health plans increasing efforts to reduce pharmaceutical costs. 3) Health reform is shifting the market to value-based care, requiring companies to demonstrate drugs' and devices' true value and economic impact compared to alternatives.
Healthcare 2020
This document discusses how the global healthcare profit pool will shift between 2010 and 2020. It predicts that the total profit pool will grow at 4% annually from $520 billion to $740 billion over this period. However, profitability will decline for most players as the sources of growth and margins change significantly between sectors and regions. Innovative pharmaceutical and medical technology companies will see much slower growth and declining margins. In contrast, providers of healthcare delivery and lower-margin sectors like generics will capture a larger share of profits. To remain competitive, companies will need to develop new business models focused on improving healthcare delivery and outcomes rather than just generating more products and procedures.
MEDTECH 2014 Opening Keynote
John Babitt, Partner, Life Sciences, Transaction Advisory Services, Ernst & Young LLP, presented at MEDTECH 2014 on The State of Change: A Look at the Evolving Healthcare Landscape and the Effect on Life Science Organizations Today and Tomorrow.
Pharmaceutical opportunities in africa
R&D less innovative but increasingly costly
Manufacturing is less sustainable in the West - shift to developing
markets
Health care costs rising globally – pressure on prices/profits
Emergence of non-communicable diseases (NCD’s)
Demand for medicines is growing more rapidly in the emerging
economies than the industrialized economies
Push towards generics over patented medicines
Focus on access to quality healthcare in Africa
Improving manufacturing/quality standards in developing countries
Increasing political support for local manufacturing in Africa
Greater focus on Africa as a “Market Opportunity
DHL_LSH_Europe_Whitepaper_MedicalDevices_Web
The document discusses the challenges facing the European medical device supply chain. It notes that the industry is facing pressures from the transition to value-based healthcare with more decision makers involved, intensifying cost pressures from payers looking to reduce costs, and stricter regulations. The supply chain must transform to address these challenges by becoming more efficient and tailored to better meet the needs of all decision makers while also reducing costs.
BioPharma Data Trends
This document discusses strategic trends in the healthcare industry, with a focus on opportunities around data and informatics. It notes that healthcare data has expanded significantly due to regulations, technology adoption, and data digitization. This has transformed business processes across biopharma, pharmacies, managed care, and point-of-care. International healthcare markets continue to see higher growth than the US. The pharmaceutical model is also evolving from large trials and blockbuster drugs to smaller trials and specialty/orphan drugs. The document identifies potential growth areas around aggregating different types of healthcare data.
Generic Pharma 2.0: 10 Potential Industry Game Changers
The generic pharmaceutical industry will look very different in 10 years due to various potential game changers. Companies will need to consider changes to their growth strategies, product selections, and business models. Ten game changers are identified that could disrupt the industry, including increased interest from big pharmaceutical companies in generics, biologic drug patent expirations, new competitors from emerging markets, and increased government protectionism favoring local drug manufacturing. To gain a competitive advantage, companies need to envision how the industry may change and develop strategies to overcome future challenges. Experts can help companies navigate this changing landscape and plot a successful path forward.
Future watch global biobanks_presentation
The document summarizes an assessment of growth opportunities for the Finnish bio-bank ecosystem. It conducted interviews with biobanks globally to understand best practices, as well as end-users to understand their needs. Key findings include:
- Oncology clinical development, genome sequencing, and digital pathology were identified as major growth opportunities.
- Interviews found that marketing outreach, defined engagement models, and strategic partnerships are important for customer relationships.
- End-user interviews focused on service alignment, criteria for selecting biobanks, and partnership fit. Understanding end-user needs is critical for growth.
Zafa pharma pest analysis
ZAFA Pharmaceutical faces several challenges in Pakistan's political, economic, social, and technological environment:
Politically, price pressures and supply issues due to strikes increase costs and hurt availability. Economically, high taxes, duties, and inflation make it difficult to determine pricing and introduce new drugs. Socially, diseases are growing rapidly but poverty prevents affordable access to needed medications. Technologically, innovation is restricted by regulations and litigation while infrastructure investment is hindered by the economic climate and power outages.
2015 trends in global medical device strategy and issues for the supply chain...
This presentation reviews critical business trends shared by major medical device companies and the implications for their manufacturing supply chain. Consolidation of device OEMs, product line and marketshare changes brought on by accountable care, and OEM desire for larger outsource partners are the dominant themes.
Future Watch summary: Future growth opportunities in global biobanks market
Future Watch summary: Future growth opportunities in global biobanks marketTeam Finland Future Watch
This Future Watch report compares the current status of forerunning biobanks in Finland, Denmark, Sweden, UK and USA, analyze the needs and views of key biobank customer segments as well as offer key recommendations for Finnish biobank to gain a larger footprint in the biobank market.White Paper - Internet Marketing Strategies For The Medical Device Industry
This is a White Paper that I wrote, while employed at Exemplum, that talks about various marketing strategies that medical device companies can use to leverage the Internet to market their products more effectivelty.
2016 trends in global medical device strategy and issues for the supply chain
In its 2016 annual review of the global medical device supply chain Manning Advisors identifies two core trends driving both OEM and supplier strategy. The first trend, consolidation, has paused to allow integration of large acquisitions made in the last three years. The second trend, changing products to compete in a fee-for-value rather than fee-for-service reimbursement environment, drives new technologies and capabilities. These trends continue to redistribute favored firms in medical devices.
2010JanFeb PharmaceuticalMarketingEurope Feature Iftheshoefits
This document discusses the changing landscape for pharmaceutical marketing and strategies to demonstrate value to payers. It outlines four categories pharmaceutical companies can fall into based on their ability to demonstrate uniqueness and compete on outcomes: 1) unique products that achieve superior outcomes through differentiation, 2) brands that leverage customer loyalty, 3) commoditized products that focus on low prices and service bundles, and 4) integrated healthcare solutions. The document recommends pharmaceutical companies adopt strategies like demonstrating superior outcomes for patient subgroups, building brands directly with consumers, and partnering to provide comprehensive healthcare programs in order to avoid becoming commoditized.
ey-pulse-of-the-industry-report
The survey summarizes the findings of a survey of US and European healthcare buyers regarding trends in medical device purchasing decisions. It finds that over the next three years, purchasing decisions will be less influenced by physicians and more influenced by hospital administrators focused on value and outcomes. Customers now prioritize reducing total healthcare costs over other outcomes when differentiating new products. As a result, medical device companies will need to demonstrate the value of their products in improving outcomes and lowering costs if they want to succeed amid increasing commoditization pressures in many product segments.
PESTLE ANAYLSIS ON PHARMACEUTICAL INDUSTRY IN ITALY
political , environmental , social, technological, legal and economical analysis of pharmaceutical industry in Italy
Research and writing skills success in 20 minutes a day
This document provides an overview of a book that teaches research and writing skills that can be learned in 20-minute daily lessons. The book contains 20 lessons that guide the reader through the entire research paper writing process from choosing a topic to finalizing a draft. It includes pre- and post-tests to measure improvement. The lessons teach essential skills like finding and evaluating sources, outlining, writing a thesis, citation styles, and more. Completing the lessons and exercises in this book will allow one to learn how to write a successful research paper in a short period of time.
UW Microbiology Research Paper on Biofilm Formation in P. aeruginosa
This document summarizes research on the role of phenazines, specifically pyocyanin, as an electron transporter in Pseudomonas aeruginosa biofilms. Studies show that pyocyanin can cycle between oxidized and reduced states, transferring electrons from NADH and allowing Pseudomonas to survive in low-oxygen environments. Research also found that pyocyanin production increased and intracellular NADH levels decreased under low oxygen conditions. Additional experiments demonstrated that pyocyanin overexpression led to more robust biofilm colonies, while pyocyanin knockout mutants generated less developed colonies. This indicates phenazines play a key role in Pseudomonas biofilm growth and survival through extracellular electron transfer.
More Related Content
What's hot
Pharma Co's in Emerging Markets - Innovation & Technology are Key to Growth
Emerging markets are predicted to account for a third of global pharmaceutical spend by the end of next year – and seen as critical for the sustained growth of leading pharma companies.
The report summarises the findings of a Cambridge Consultants workshop held in Mumbai, India, earlier this year. The product design and development firm brought together senior personnel from both Indian and multinational pharma companies to debate whether emerging markets can be an opportunity to drive sustainable growth.
The consensus was that the term ‘emerging markets’ covers nations in parts of Africa, the Middle East and South East Asia, as well as the more traditional countries of Brazil, Russia, India and China. But all the delegates said emerging markets cannot be grouped into a single cluster to chalk out common strategies. Clustering markets around parameters such as regulatory pathways or therapeutic applications was considered the best approach.
“Emerging markets are facing rapid growth of chronic ‘Western’ diseases like diabetes, hypertension, chronic respiratory problems, cancer, heart disease and neurological disorders,” said Ambuj Jain, India general manager at Cambridge Consultants. “In some cases, conditions like diabetes are turning into near-epidemic situations.
“In India, for example, the prevalence of diabetes and cancer is projected to rise by 25-40% over the next 10 years. This shift gives pharma companies an opportunity to market their global products in emerging markets, backed by tested ‘go-to-market’ strategies and operating models.”
The report says key barriers which need to be addressed in many emerging markets are the affordability and accessibility of medicines. Improvements in affordability will be driven by rising disposable incomes and increasing insurance coverage. Growth in accessibility will come from increases in government spending and medical infrastructure, and new business models for rural areas. The acceptability of medicines is also expected to rise, as a result of the growth in chronic conditions – and the resulting increase in the self-administration of drugs.
Workshop delegate Sanjay Bhanushali, a director of global pharma company Cipla, said: “Emerging markets are critical for the sustained growth of leading pharmaceutical organisations. They represent a significant proportion of the world’s population and many of their governments are increasingly focusing on improving healthcare. Innovation and technology – with the emphasis on patient and stakeholder needs – will be crucial to success in these markets.”
Diagnostics was seen by the workshop delegates as a key focus area where innovation can drive sustained growth.
Pharma trends in bric economies
This document discusses trends in emerging pharmaceutical markets, focusing on Brazil, Russia, India, and China. It provides an overview of the current healthcare systems and pharmaceutical markets in each country. Some key points discussed include growth patterns in developed markets flattening while emerging markets see significant growth potential. The document also outlines future trends in each country such as increasing regulation, emphasis on generics, and strategies pharmaceutical companies can employ to succeed in these emerging markets.
Medical devices equipped for the future
The document discusses disruptive changes underway in the medical devices industry that will transform it over the next 5 years. It identifies 5 major disruptors: 1) a power shift to payers and providers who are focusing more on cost and value-based evidence, 2) heightened regulatory scrutiny that is increasing compliance costs, 3) unclear sources of innovation as R&D spending yields diminishing returns, 4) new healthcare delivery models that are shifting care settings out of hospitals, and 5) a need to serve lower socioeconomic classes in developing markets. The disruptors threaten $34 billion in industry profits by 2020 but taking appropriate measures could help maintain revenue growth and offset margin declines, preserving significant value for medical device companies.
Learn How to Beat Problems Feb23, 2007
The document discusses the Bulgarian pharmaceutical market and opportunities for growth. It notes that Bulgaria provides political and economic stability with low costs and 5.5% annual growth. The pharmaceutical industry is moving towards generics and partnerships to lower costs and access international markets. It introduces Tchaikapharma as part of the vertically integrated CL BioPharma Group, which provides manufacturing, distribution, and clinical services to help companies access the Bulgarian market and beyond.
2015 Medical Device Outlook - Deloitte
United States life sciences companies face numerous challenges in 2015 related to market changes, consolidation, pricing pressures, and health reform. Six key issues are highlighted: 1) Market reconfiguration and consolidation due to factors like expiring patents are driving the need for companies to reassess strategies and explore M&A opportunities. 2) Pricing pressures exist from government efforts to control costs and from health plans increasing efforts to reduce pharmaceutical costs. 3) Health reform is shifting the market to value-based care, requiring companies to demonstrate drugs' and devices' true value and economic impact compared to alternatives.
Healthcare 2020
This document discusses how the global healthcare profit pool will shift between 2010 and 2020. It predicts that the total profit pool will grow at 4% annually from $520 billion to $740 billion over this period. However, profitability will decline for most players as the sources of growth and margins change significantly between sectors and regions. Innovative pharmaceutical and medical technology companies will see much slower growth and declining margins. In contrast, providers of healthcare delivery and lower-margin sectors like generics will capture a larger share of profits. To remain competitive, companies will need to develop new business models focused on improving healthcare delivery and outcomes rather than just generating more products and procedures.
MEDTECH 2014 Opening Keynote
John Babitt, Partner, Life Sciences, Transaction Advisory Services, Ernst & Young LLP, presented at MEDTECH 2014 on The State of Change: A Look at the Evolving Healthcare Landscape and the Effect on Life Science Organizations Today and Tomorrow.
Pharmaceutical opportunities in africa
R&D less innovative but increasingly costly
Manufacturing is less sustainable in the West - shift to developing
markets
Health care costs rising globally – pressure on prices/profits
Emergence of non-communicable diseases (NCD’s)
Demand for medicines is growing more rapidly in the emerging
economies than the industrialized economies
Push towards generics over patented medicines
Focus on access to quality healthcare in Africa
Improving manufacturing/quality standards in developing countries
Increasing political support for local manufacturing in Africa
Greater focus on Africa as a “Market Opportunity
DHL_LSH_Europe_Whitepaper_MedicalDevices_Web
The document discusses the challenges facing the European medical device supply chain. It notes that the industry is facing pressures from the transition to value-based healthcare with more decision makers involved, intensifying cost pressures from payers looking to reduce costs, and stricter regulations. The supply chain must transform to address these challenges by becoming more efficient and tailored to better meet the needs of all decision makers while also reducing costs.
BioPharma Data Trends
This document discusses strategic trends in the healthcare industry, with a focus on opportunities around data and informatics. It notes that healthcare data has expanded significantly due to regulations, technology adoption, and data digitization. This has transformed business processes across biopharma, pharmacies, managed care, and point-of-care. International healthcare markets continue to see higher growth than the US. The pharmaceutical model is also evolving from large trials and blockbuster drugs to smaller trials and specialty/orphan drugs. The document identifies potential growth areas around aggregating different types of healthcare data.
Generic Pharma 2.0: 10 Potential Industry Game Changers
The generic pharmaceutical industry will look very different in 10 years due to various potential game changers. Companies will need to consider changes to their growth strategies, product selections, and business models. Ten game changers are identified that could disrupt the industry, including increased interest from big pharmaceutical companies in generics, biologic drug patent expirations, new competitors from emerging markets, and increased government protectionism favoring local drug manufacturing. To gain a competitive advantage, companies need to envision how the industry may change and develop strategies to overcome future challenges. Experts can help companies navigate this changing landscape and plot a successful path forward.
Future watch global biobanks_presentation
The document summarizes an assessment of growth opportunities for the Finnish bio-bank ecosystem. It conducted interviews with biobanks globally to understand best practices, as well as end-users to understand their needs. Key findings include:
- Oncology clinical development, genome sequencing, and digital pathology were identified as major growth opportunities.
- Interviews found that marketing outreach, defined engagement models, and strategic partnerships are important for customer relationships.
- End-user interviews focused on service alignment, criteria for selecting biobanks, and partnership fit. Understanding end-user needs is critical for growth.
Zafa pharma pest analysis
ZAFA Pharmaceutical faces several challenges in Pakistan's political, economic, social, and technological environment:
Politically, price pressures and supply issues due to strikes increase costs and hurt availability. Economically, high taxes, duties, and inflation make it difficult to determine pricing and introduce new drugs. Socially, diseases are growing rapidly but poverty prevents affordable access to needed medications. Technologically, innovation is restricted by regulations and litigation while infrastructure investment is hindered by the economic climate and power outages.
2015 trends in global medical device strategy and issues for the supply chain...
This presentation reviews critical business trends shared by major medical device companies and the implications for their manufacturing supply chain. Consolidation of device OEMs, product line and marketshare changes brought on by accountable care, and OEM desire for larger outsource partners are the dominant themes.
Future Watch summary: Future growth opportunities in global biobanks market
Future Watch summary: Future growth opportunities in global biobanks marketTeam Finland Future Watch
This Future Watch report compares the current status of forerunning biobanks in Finland, Denmark, Sweden, UK and USA, analyze the needs and views of key biobank customer segments as well as offer key recommendations for Finnish biobank to gain a larger footprint in the biobank market.White Paper - Internet Marketing Strategies For The Medical Device Industry
This is a White Paper that I wrote, while employed at Exemplum, that talks about various marketing strategies that medical device companies can use to leverage the Internet to market their products more effectivelty.
2016 trends in global medical device strategy and issues for the supply chain
In its 2016 annual review of the global medical device supply chain Manning Advisors identifies two core trends driving both OEM and supplier strategy. The first trend, consolidation, has paused to allow integration of large acquisitions made in the last three years. The second trend, changing products to compete in a fee-for-value rather than fee-for-service reimbursement environment, drives new technologies and capabilities. These trends continue to redistribute favored firms in medical devices.
2010JanFeb PharmaceuticalMarketingEurope Feature Iftheshoefits
This document discusses the changing landscape for pharmaceutical marketing and strategies to demonstrate value to payers. It outlines four categories pharmaceutical companies can fall into based on their ability to demonstrate uniqueness and compete on outcomes: 1) unique products that achieve superior outcomes through differentiation, 2) brands that leverage customer loyalty, 3) commoditized products that focus on low prices and service bundles, and 4) integrated healthcare solutions. The document recommends pharmaceutical companies adopt strategies like demonstrating superior outcomes for patient subgroups, building brands directly with consumers, and partnering to provide comprehensive healthcare programs in order to avoid becoming commoditized.
ey-pulse-of-the-industry-report
The survey summarizes the findings of a survey of US and European healthcare buyers regarding trends in medical device purchasing decisions. It finds that over the next three years, purchasing decisions will be less influenced by physicians and more influenced by hospital administrators focused on value and outcomes. Customers now prioritize reducing total healthcare costs over other outcomes when differentiating new products. As a result, medical device companies will need to demonstrate the value of their products in improving outcomes and lowering costs if they want to succeed amid increasing commoditization pressures in many product segments.
PESTLE ANAYLSIS ON PHARMACEUTICAL INDUSTRY IN ITALY
political , environmental , social, technological, legal and economical analysis of pharmaceutical industry in Italy
What's hot (20)
Pharma Co's in Emerging Markets - Innovation & Technology are Key to Growth
Pharma Co's in Emerging Markets - Innovation & Technology are Key to Growth
Generic Pharma 2.0: 10 Potential Industry Game Changers
Generic Pharma 2.0: 10 Potential Industry Game Changers
2015 trends in global medical device strategy and issues for the supply chain...
2015 trends in global medical device strategy and issues for the supply chain...
Future Watch summary: Future growth opportunities in global biobanks market
Future Watch summary: Future growth opportunities in global biobanks market
White Paper - Internet Marketing Strategies For The Medical Device Industry
White Paper - Internet Marketing Strategies For The Medical Device Industry
2016 trends in global medical device strategy and issues for the supply chain
2016 trends in global medical device strategy and issues for the supply chain
2010JanFeb PharmaceuticalMarketingEurope Feature Iftheshoefits
2010JanFeb PharmaceuticalMarketingEurope Feature Iftheshoefits
PESTLE ANAYLSIS ON PHARMACEUTICAL INDUSTRY IN ITALY
PESTLE ANAYLSIS ON PHARMACEUTICAL INDUSTRY IN ITALY
Viewers also liked
Research and writing skills success in 20 minutes a day
This document provides an overview of a book that teaches research and writing skills that can be learned in 20-minute daily lessons. The book contains 20 lessons that guide the reader through the entire research paper writing process from choosing a topic to finalizing a draft. It includes pre- and post-tests to measure improvement. The lessons teach essential skills like finding and evaluating sources, outlining, writing a thesis, citation styles, and more. Completing the lessons and exercises in this book will allow one to learn how to write a successful research paper in a short period of time.
UW Microbiology Research Paper on Biofilm Formation in P. aeruginosa
This document summarizes research on the role of phenazines, specifically pyocyanin, as an electron transporter in Pseudomonas aeruginosa biofilms. Studies show that pyocyanin can cycle between oxidized and reduced states, transferring electrons from NADH and allowing Pseudomonas to survive in low-oxygen environments. Research also found that pyocyanin production increased and intracellular NADH levels decreased under low oxygen conditions. Additional experiments demonstrated that pyocyanin overexpression led to more robust biofilm colonies, while pyocyanin knockout mutants generated less developed colonies. This indicates phenazines play a key role in Pseudomonas biofilm growth and survival through extracellular electron transfer.
Inclusion in the Classroom
This document discusses inclusion in the classroom and presents arguments both for and against the practice of inclusion. It begins by defining inclusion and providing background on its history and use. It then examines who may benefit from inclusion and provides statistics on its current use. The document outlines arguments in favor of inclusion, such as the experiences of students who have thrived in inclusive environments and the ethical reasons for supporting inclusion. However, it also acknowledges opposition to inclusion based on concerns about adequate funding, fairness to other students, and the appropriate role of schools. The document concludes by reflecting on both benefits and drawbacks of inclusion and its potential future development.
Group 3 final term paper in social psychology
This document contains responses from multiple students summarizing how interpersonal relationships work, how to overcome prejudices, how social psychology differs from sociology, and how attitudes are formed. The students provided short answers to each question based on their understanding of the relevant concepts from psychology.
Play Therapy research paper
This document discusses an ecosystemic play therapy model for addressing the whole child. It explores how daily stressors from a child's family, school, community, and environment can influence their behaviors. These stressors include academic demands, family problems, financial issues, and exposure to violence. The ecosystemic play therapy model considers a child's problems and therapy within the context of their entire ecosystem. The role of the therapist is to help the child understand treatment, establish rapport, engage in problem-solving, and motivate behavior change by setting limits with the child and caregivers. The overall approach focuses on identifying the underlying causes of a child's behaviors and changing their thought processes to improve behaviors.
Hannah S. Senior Project Research Paper
The document discusses the physical, social, and educational benefits of horseback riding therapy for people with disabilities. It explains that hippotherapy focuses on using horse movement to improve physical functioning, while therapeutic riding aims to improve riding skills. Both can help build balance, muscle strength, and motor skills. Socially, horseback riding therapy allows people to form relationships and overcome fears. It also incorporates educational activities to help riders learn skills like sequencing and math in a fun way. The document argues that horseback riding provides benefits beyond traditional physical therapy for people with disabilities.
Corporate compliance plan
Riordan Manufacturing is an international plastic manufacturing company that is planning to relocate its China operations from Hang Zhou province to Shanghai within five years. Before making this move, there are some legal and compliance issues that must be addressed. First, the move must be allowable according to the original contract terms and local Chinese laws. Second, terminating local employees must be done through alternative dispute resolution rather than in court to avoid breach of contract claims. Setting up the new Shanghai operations will also require ensuring compliance with international laws, regulations on products and intellectual property, and properly addressing issues around contracts and liability with local vendors and suppliers.
Alternative energy research paper
This is a research paper I wrote about alternative energy, what it is, why we need it and specific types we can use. I am going to upload this paper to my Wiki, and Weebly site.
Early treatment research paper
1) The document discusses the controversy around early orthodontic treatment versus later treatment. While early treatment can prevent larger issues later on, it may also mean the child needs additional treatment in the future.
2) The impact of early treatment is that it is more effective at manipulating the jaw and skeletal structure while growth is still occurring. However, waiting risks longer treatment times or issues being noticed too late.
3) Resolutions to orthodontic issues include early phase treatments, making braces more appealing to encourage compliance, and interventions like palate expanders which can only be used early on. The outlook is brighter with early treatment as more can be adjusted during growth.
Research on Jane Austen
Jane Austen was born in Hampshire, England in 1775. She came from a large, close-knit family and showed an early talent for writing. Her father supported her writing by providing books and materials. After her father's retirement, the family moved to Bath where Jane was unhappy and her writing declined. After her father's death, her brothers provided financial support for her mother and sisters. Jane found happiness writing again after moving to Southampton. Her health deteriorated and she died in 1817 at the age of 41.
Algernon paper structure
The document provides guidance on writing a response to literature essay, including outlining the typical structure and components. It discusses including an introductory paragraph with a thesis statement, three body paragraphs with topic sentences, concrete details from the text, and commentary/analysis. It also provides examples of hooks, tags, thesis statements, topic sentences, transitions, and concrete details that could be used when writing about the short story "Flowers for Algernon."
Research paper writing (abbreviated version)
Brief intro to writing a research paper. Abridged from the original version for high school use. Covers purpose and post-writing.
Term Paper on Changing Trend Of Marriage : A Sociological Research Based on D...
This document is a term paper submitted by six students to their sociology professor at BRAC University. It analyzes the changing trends of marriage in Dhaka based on interviews with a focus group of 12 recently married individuals aged 25-40. The paper finds that mate selection has shifted from an arrangement by parents to a personal choice. While some faced social issues like interference from family, most were eventually accepted by relatives. The paper is divided into sections on methodology, findings from interviews, and conclusions. It uses quotes from interviews to support its analysis of how people in Dhaka are adapting to new ways of choosing partners and getting married.
Assembly Line Research Paper
1) Henry Ford developed the assembly line at his Highland Park plant in Michigan in 1913, which was the culmination of decades of technological developments.
2) Key developments included interchangeable parts, portable electric motors that allowed for flexible factory layouts, and the concept of a moving assembly line where parts were brought to stationary workers.
3) These innovations enabled Ford to realize his goal of mass production and producing affordable cars for the masses using the most efficient methods possible.
Myers 9e ch1 - Thinking Critically with Psychological Science
This document provides an overview of key concepts from Psychology (9th Edition) by David Myers. It discusses the need for psychological science to use empirical evidence rather than intuition alone. It describes how psychologists ask and answer questions using the scientific method, including description, correlation, and experimentation. Statistical reasoning is important for interpreting data and making inferences. Frequently asked questions about psychology are also addressed, such as whether laboratory experiments can illuminate everyday life and if psychology experiments on humans are ethical.
The European Research Centre for Book and Paper Conservation-Restoration
The European Research Centre for Book and Paper Conservation-RestorationICARUS - International Centre for Archival Research
This presentation introduces the European Reserarch Centre for Book
and Paper Conservation-Restoration, its projects and further education
courses. Furthermore the studios for conservation are presented and the
possibilies how archives could cooperate with the Centre are listed.Jessica garrett research paper 2011 12
Italian food plays a central role in Italian culture, with strong traditions passed down through families over generations. Cooking and sharing meals are important social activities in Italy. While Italian cuisine has been influenced by other cultures, regional differences exist. Food remains a source of pride for Italians, and a key part of celebrations and holidays. The traditions and techniques of Italian cooking have spread worldwide but are difficult for other cultures to fully replicate.
Writing a research protocol 2011
The document provides guidance on writing a research protocol, including its key components and characteristics. A well-written protocol should clearly state the research question/problem and aim, justify the need for the study, and outline the methodology in sufficient detail. Key sections include an introduction with objectives, methods, and ethical/gender considerations. The protocol guides the research plan and must be adhered to strictly.
The Action Research Process-APA Guidelines
The document outlines the action research process which involves observing a situation, analyzing it, adjusting a plan, acting on the plan, observing the results, reflecting on them, revising the plan if needed, and repeating the process. It also provides guidelines for formatting papers in APA style, including specifications for fonts, margins, page headers and numbers when writing reports on books, periodicals, online journals, websites or blogs.
History research outline
The document outlines a research paper on the Battle of the Alamo. It will discuss events before the battle like the Law of April 6, 1830. It will describe what happened in the battle, including how only some women and children survived. It will also discuss the aftermath, such as Texian forces yelling "Remember the Alamo" at the Battle of San Jacinto. The paper is organized into an introduction, sections on pre-battle events, the battle itself, and aftermath. It lists several cited sources that will be used in the paper.
Viewers also liked (20)
Research and writing skills success in 20 minutes a day
Research and writing skills success in 20 minutes a day
UW Microbiology Research Paper on Biofilm Formation in P. aeruginosa
UW Microbiology Research Paper on Biofilm Formation in P. aeruginosa
Term Paper on Changing Trend Of Marriage : A Sociological Research Based on D...
Term Paper on Changing Trend Of Marriage : A Sociological Research Based on D...
Myers 9e ch1 - Thinking Critically with Psychological Science
Myers 9e ch1 - Thinking Critically with Psychological Science
The European Research Centre for Book and Paper Conservation-Restoration
The European Research Centre for Book and Paper Conservation-Restoration
Similar to Summary Presentation based on healthcare white paper by grail research
Final
This document provides an overview of research methodology for studying the Indian pharmaceutical market and the effect of healthcare products. The objectives are to understand the market contribution of healthcare products and evaluate consumers' and doctors' attitudes towards these products. Secondary research will gather data from company sources, while primary research will involve interviews with chemists, doctors, and consumers. The study aims to benefit researchers, the sponsoring organization, and colleagues by providing insights into opportunities in the domestic pharmaceutical market.
Navigating the Ever-Evolving Healthcare Market: Growth, Challenges, and IoT I...
Explore a wealth of healthcare insights with Ken Research. Our comprehensive reports provide in-depth analysis and valuable data across various healthcare topics. Whether you're interested in pharmaceuticals, medical devices, or healthcare services, our research covers a wide range of areas. Stay informed about market trends and regulatory updates to make well-informed decisions in the dynamic healthcare sector. Ken Research empowers your industry strategies with the knowledge and analysis you need. Dive into our extensive library of healthcare reports to stay ahead of the curve in this competitive and evolving industry.
Shaping_the_biosimiliars_opportunity_A_global_perspective_on_the_evolving_bio...
This document discusses the evolving global biosimilars landscape and opportunities. It notes that after slow initial growth, biosimilars are poised for accelerated growth over the next decade due to expiring biologic drug patents, new US legislation, and payer pressure to reduce costs. By 2015, biosimilars sales are projected to reach $1.9-2.6 billion, up significantly from 2011 levels. Key drivers include major biologics like Herceptin, Enbrel and Humalog losing patent protection and increased focus on areas like oncology, diabetes and rheumatoid arthritis. A diverse range of competitors from generic drugmakers to large biopharmaceutical companies are pursuing biosimilar programs. However, realization of
The 10 companies booming in healthcare sector small
Development is a continuous process in any sector. It brings in more comfort, more precision, and more enhanced way of living.Acknowledging the remarkable contribution of the leading companies in the care sector, we bring to you the special issue of “The 10 Companies Booming in Healthcare Sector”.
Passing the healthcare innovation torch: from medicinal chemistry, though bio...
In the middle of the 20th Century, pharmaceutical companies were highly respected and patients depended on their physicians to make healthcare decisions. Drugs were a key part of a physician’s ‘toolkit’.
As we entered the era of the blockbuster drugs, most were small molecules made by chemical synthesis, but biotechnology was starting to emerge as a possible source of new therapeutics. Meanwhile, direct-to-consumer pharmaceutical advertising began to empower patients.
Fast forward to today, and we see pharmaceutical companies suffering degraded reputations and values, patients further empowered by the Internet and social media, and average life expectancies increased by a decade. Digital health technologies are poised to explode and the top 10 pharmaceuticals by sales will soon all be biologicals!
Niche buster drug
A brief description about opportunities in niche buster market which can be a alternative of blockbuster strategy..
Medical Instrument and Supply Manufacturing Industry Report
The document provides an overview of the medical instrument and supply manufacturing industry. It discusses key factors such as an aging population driving increased demand, regulations from the FDA and PPACA, and consolidation in the industry with larger companies acquiring smaller innovative ones. While the industry faces pressures from regulations and increasing wages, overall growth is expected to continue due to demographic trends and the need for ongoing innovation in medical technology. The industry provides opportunities for Oregon companies if they maintain innovation and low costs.
Pharmaceutical industry pestel analysis
The pharmaceutical industry in India is a rapidly growing sector that produces low-cost, high-quality drugs. It has a total market size of over $20 billion and has grown at around 12.5% annually over the past five years. Key players in the industry include Ranbaxy, Dr. Reddy's, Cipla, and Lupin. A PESTEL analysis identified political issues like price controls, social factors like an aging population and increased patient expectations, economic challenges from the global crisis, opportunities from new technologies, and an increasing focus on the environmental impact of the industry.
Biosimilars white paper asia pac 311012
This document provides a global perspective on the evolving biosimilars landscape and market. It finds that after slow initial growth, the biosimilars market is poised for accelerated expansion between 2015-2020 as major biologics lose patent protection, US legislation establishes a regulatory pathway, and payers increase adoption to control costs. The market could reach $1.9-2.6 billion by 2015, up from $378 million currently, with the largest opportunities in oncology, diabetes, and rheumatoid arthritis. Key drivers include cost pressures on healthcare systems and the availability of lower-cost biosimilar alternatives to expensive biologic drugs. However, significant barriers remain due to varying regulations worldwide and resistance from biologics manufacturers.
Outlook 2011 presentation
The document provides an outlook on the global bio-pharmaceutical sector in 2011. It discusses factors that are positive for the sector such as increased R&D spending and novel drug approvals. Challenges mentioned include regulatory hurdles, biosimilars, and patent expiries. The document analyzes investment opportunities in areas like HCV, autoimmune diseases, and rare genetic disorders. It also examines issues facing mature biotechs and provides a valuation methodology.
Emerging markets: healthcare need & commercial opportunity
1) There is a need for equitable access to quality healthcare in emerging markets, including affordable essential care and treatment for diseases like diabetes, cardiovascular issues, and infectious diseases.
2) Emerging markets represent a major commercial opportunity for pharmaceutical companies, with industry forecasts showing 12% annual growth and emerging markets making up 30-50% of global pharmaceutical sales by 2020.
3) However, there are challenges to addressing healthcare needs and realizing commercial opportunities in emerging markets, including issues around access, reimbursement, intellectual property protection, and corruption.
pwc cii-pharma_summit_enhancing value through partnerships
India Pharma Inc. explores how alliances and partnerships are enhancing value in the pharmaceutical industry. The global context of rising healthcare costs, impending patent cliffs, and declining R&D productivity is driving companies to collaborate. In India, the growing domestic market and low-cost manufacturing are attracting foreign investment through mergers, acquisitions, and partnerships focused on product sourcing, drug discovery, and marketing. Successful partnerships depend on factors like quality, management control, cultural differences, and thorough due diligence. Collaboration across the pharmaceutical industry and with other sectors will be important for sustainable growth.
2012 EY Biotech Report
The document discusses the need for a new paradigm for funding and conducting biotech research and development (R&D) given constraints in the current financing environment. It proposes a model called Holistic Open Learning Networks (HOLNets) that would bring together diverse participants like healthcare providers, patient groups, data analytics firms, and social media networks. HOLNets could fundamentally change R&D by encouraging data sharing, allowing researchers to learn from each other in real time, and taking advantage of the shift in healthcare to outcomes-focused and data-driven models.
Pharma Market Research Report Dec 2013
9th annual predictions issue in which various pharma MR leaders prognosticate about industry trends in 2014 and beyond
Health-Tech: Endless opportunities & endless disruption
This document provides an overview of the health tech industry and key trends. It discusses how the industry has adopted digital technologies across areas like drug manufacturing, clinical trials, hospitals, and care services. The COVID-19 pandemic further increased adoption rates. The document analyzes funding and deal size data from the past 5 years to identify fast growing segments like telemedicine, anti-counterfeiting tech, and the rise of tech giants in healthcare investing. Post-pandemic, virtual consultations are expected to become more mainstream. The future of healthcare is predicted to rely more on technologies like artificial intelligence, digital tools, and data analytics.
Pharma 2020: Marketing the future Which path will you take?
This document discusses key trends reshaping the pharmaceutical marketplace and how pharmaceutical companies will need to change their marketing and sales models to adapt. It outlines that healthcare payers and providers are gaining more influence over what drugs are prescribed and how they are valued. Pharmaceutical companies will need to prove their drugs deliver clear benefits over alternatives to justify their prices. Direct-to-consumer advertising is becoming less effective at driving sales, while e-prescribing may further reduce drug companies' influence over prescribing decisions unless they collaborate with healthcare stakeholders. Major changes will be needed to the traditional marketing and sales models to be successful in this changing environment.
biotech
The document recommends an overweight position in the healthcare biotechnology industry. Major companies are seeing double digit revenue growth and high profit margins due to limited competition from patents. However, government regulation poses a threat if it imposes price caps or reduces patent lives. Additionally, companies rely on a small number of "star drugs" whose expiration or replacement could significantly harm their value.
The 10 Companies Booming in Healthcare Sector
Acknowledging the remarkable contribution of the leading companies in the care sector, we bring to you the special issue of “The 10 Companies Booming in Healthcare Sector”. This edition portrays the inspiring stories of the listed pre-eminent organizations that are shaping the future of healthcare through innovation and dedication.
Brenda Canty - Johnson & Johnson Laboratories
The document discusses trends in the pharmaceutical industry through 2020. It notes ongoing challenges like unmet medical needs, aging populations, and chronic diseases. Future drivers include these aging and underserved populations in developing countries and effects of global warming. The industry will see more integrated value chains between pharma, payers, and providers. Treatment costs are unsustainable so the focus will shift to prevention and pharma providing full healthcare packages with payment for outcomes not just treatment. Pharma business models will change significantly, moving from blockbuster drug sales to more services across the healthcare spectrum. Laboratories of the future will need to develop new capabilities and talent to achieve this changed vision.
Global market size in drug lead and precursor
The document discusses the global market size of drug leads, precursors, and drug discovery outsourcing. It provides insights into market trends such as:
1) The global drug discovery outsourcing market was estimated at $2.19 billion in 2016 and is expected to witness rapid growth due to increased outsourcing and investments in drug discovery R&D.
2) North America dominated the market in 2016, while Asia Pacific is expected to grow the fastest during 2020-2025 due to growth in pharmaceutical industries and less stringent regulations.
3) The beta-carotene market is driven by its use as a natural colorant and precursor to vitamin A to treat deficiencies, and in pharmaceuticals and
Similar to Summary Presentation based on healthcare white paper by grail research (20)
Navigating the Ever-Evolving Healthcare Market: Growth, Challenges, and IoT I...
Navigating the Ever-Evolving Healthcare Market: Growth, Challenges, and IoT I...
Shaping_the_biosimiliars_opportunity_A_global_perspective_on_the_evolving_bio...
Shaping_the_biosimiliars_opportunity_A_global_perspective_on_the_evolving_bio...
The 10 companies booming in healthcare sector small
The 10 companies booming in healthcare sector small
Passing the healthcare innovation torch: from medicinal chemistry, though bio...
Passing the healthcare innovation torch: from medicinal chemistry, though bio...
Medical Instrument and Supply Manufacturing Industry Report
Medical Instrument and Supply Manufacturing Industry Report
Emerging markets: healthcare need & commercial opportunity
Emerging markets: healthcare need & commercial opportunity
pwc cii-pharma_summit_enhancing value through partnerships
pwc cii-pharma_summit_enhancing value through partnerships
Health-Tech: Endless opportunities & endless disruption
Health-Tech: Endless opportunities & endless disruption
Pharma 2020: Marketing the future Which path will you take?
Pharma 2020: Marketing the future Which path will you take?
Recently uploaded
What are the different types of Dental implants.
Are you looking for a long-lasting solution to your missing tooth?
Dental implants are the most common type of method for replacing the missing tooth. Unlike dentures or bridges, implants are surgically placed in the jawbone. In layman’s terms, a dental implant is similar to the natural root of the tooth. It offers a stable foundation for the artificial tooth giving it the look, feel, and function similar to the natural tooth.
Foundation of Yoga, YCB Level-3, Unit-1
Unit -1 of Yoga certification board, level 3, all topics covered. An exam conducted by ministry of Ayush for yoga enthusiastic students.
June 2024 Oncology Cartoons By Dr Kanhu Charan Patro
une 2024 Oncology Cartoons By Dr Kanhu Charan Patro
Breast cancer: Post menopausal endocrine therapy
Breast cancer in postmenopausal women with hormone receptor-positive (HR+) status is a common and complex condition that necessitates a multifaceted approach to management. HR+ breast cancer means that the cancer cells grow in response to hormones such as estrogen and progesterone. This subtype is prevalent among postmenopausal women and typically exhibits a more indolent course compared to other forms of breast cancer, which allows for a variety of treatment options.
Diagnosis and Staging
The diagnosis of HR+ breast cancer begins with clinical evaluation, imaging, and biopsy. Imaging modalities such as mammography, ultrasound, and MRI help in assessing the extent of the disease. Histopathological examination and immunohistochemical staining of the biopsy sample confirm the diagnosis and hormone receptor status by identifying the presence of estrogen receptors (ER) and progesterone receptors (PR) on the tumor cells.
Staging involves determining the size of the tumor (T), the involvement of regional lymph nodes (N), and the presence of distant metastasis (M). The American Joint Committee on Cancer (AJCC) staging system is commonly used. Accurate staging is critical as it guides treatment decisions.
Treatment Options
Endocrine Therapy
Endocrine therapy is the cornerstone of treatment for HR+ breast cancer in postmenopausal women. The primary goal is to reduce the levels of estrogen or block its effects on cancer cells. Commonly used agents include:
Selective Estrogen Receptor Modulators (SERMs): Tamoxifen is a SERM that binds to estrogen receptors, blocking estrogen from stimulating breast cancer cells. It is effective but may have side effects such as increased risk of endometrial cancer and thromboembolic events.
Aromatase Inhibitors (AIs): These drugs, including anastrozole, letrozole, and exemestane, lower estrogen levels by inhibiting the aromatase enzyme, which converts androgens to estrogen in peripheral tissues. AIs are generally preferred in postmenopausal women due to their efficacy and safety profile compared to tamoxifen.
Selective Estrogen Receptor Downregulators (SERDs): Fulvestrant is a SERD that degrades estrogen receptors and is used in cases where resistance to other endocrine therapies develops.
Combination Therapies
Combining endocrine therapy with other treatments enhances efficacy. Examples include:
Endocrine Therapy with CDK4/6 Inhibitors: Palbociclib, ribociclib, and abemaciclib are CDK4/6 inhibitors that, when combined with endocrine therapy, significantly improve progression-free survival in advanced HR+ breast cancer.
Endocrine Therapy with mTOR Inhibitors: Everolimus, an mTOR inhibitor, can be added to endocrine therapy for patients who have developed resistance to aromatase inhibitors.
Chemotherapy
Chemotherapy is generally reserved for patients with high-risk features, such as large tumor size, high-grade histology, or extensive lymph node involvement. Regimens often include anthracyclines and taxanes.
Post-Menstrual Smell- When to Suspect Vaginitis.pptx
Do you have abnormal smell after periods? It may be vaginitis. Do not worry, herbal medicine Fuyan Pill can help you get a cure.
Acute Gout Care & Urate Lowering Therapy .pdf
In this document , the management of acute gout attacks and a description of urate lowering therapy is mentioned.
Cervical Disc Arthroplasty ORSI 2024.pptx
Indication and installation of a mobile cervical disc prosthesis. Benefits of the PRODISC C VIVO mobile disc prosthesis (Centinel Spine)
Skin Diseases That Happen During Summer.
Summer is a time for fun in the sun, but the heat and humidity can also wreak havoc on your skin. From itchy rashes to unwanted pigmentation, several skin conditions become more prevalent during these warmer months.
Pune Call Girls 7339748667 AVAILABLE HOT GIRLS AUNTY BOOK NOW
Pune Call Girls 7339748667 AVAILABLE HOT GIRLS AUNTY BOOK NOW
acne vulgaris -Mpharm (2nd semester) Cosmetics and cosmeceuticals
cosmetics and cosmeceuticals
Muskan
mpharm
2nd semester
Guru Gobind Singh college of pharmacy, yamunanagar, haryana
What is Obesity? How to overcome Obesity?
Obesity is a chronic complex disease defined by excessive fat deposits that can impair health.
Osvaldo Bernardo Muchanga-GASTROINTESTINAL INFECTIONS AND GASTRITIS-2024.pdf
Osvaldo Bernardo Muchanga-GASTROINTESTINAL INFECTIONS AND GASTRITIS-2024.pdfOsvaldo Bernardo Muchanga
GASTROINTESTINAL INFECTIONS AND GASTRITIS
Osvaldo Bernardo Muchanga
Gastrointestinal Infections
GASTROINTESTINAL INFECTIONS result from the ingestion of pathogens that cause infections at the level of this tract, generally being transmitted by food, water and hands contaminated by microorganisms such as E. coli, Salmonella, Shigella, Vibrio cholerae, Campylobacter, Staphylococcus, Rotavirus among others that are generally contained in feces, thus configuring a FECAL-ORAL type of transmission.
Among the factors that lead to the occurrence of gastrointestinal infections are the hygienic and sanitary deficiencies that characterize our markets and other places where raw or cooked food is sold, poor environmental sanitation in communities, deficiencies in water treatment (or in the process of its plumbing), risky hygienic-sanitary habits (not washing hands after major and/or minor needs), among others.
These are generally consequences (signs and symptoms) resulting from gastrointestinal infections: diarrhea, vomiting, fever and malaise, among others.
The treatment consists of replacing lost liquids and electrolytes (drinking drinking water and other recommended liquids, including consumption of juicy fruits such as papayas, apples, pears, among others that contain water in their composition).
To prevent this, it is necessary to promote health education, improve the hygienic-sanitary conditions of markets and communities in general as a way of promoting, preserving and prolonging PUBLIC HEALTH.
Gastritis and Gastric Health
Gastric Health is one of the most relevant concerns in human health, with gastrointestinal infections being among the main illnesses that affect humans.
Among gastric problems, we have GASTRITIS AND GASTRIC ULCERS as the main public health problems. Gastritis and gastric ulcers normally result from inflammation and corrosion of the walls of the stomach (gastric mucosa) and are generally associated (caused) by the bacterium Helicobacter pylor, which, according to the literature, this bacterium settles on these walls (of the stomach) and starts to release urease that ends up altering the normal pH of the stomach (acid), which leads to inflammation and corrosion of the mucous membranes and consequent gastritis or ulcers, respectively.
In addition to bacterial infections, gastritis and gastric ulcers are associated with several factors, with emphasis on prolonged fasting, chemical substances including drugs, alcohol, foods with strong seasonings including chilli, which ends up causing inflammation of the stomach walls and/or corrosion. of the same, resulting in the appearance of wounds and consequent gastritis or ulcers, respectively.
Among patients with gastritis and/or ulcers, one of the dilemmas is associated with the foods to consume in order to minimize the sensation of pain and discomfort. The Nervous and Chemical Regulation of Respiration
These lecture slides, by Dr Sidra Arshad, offer a simplified look into the mechanisms involved in the regulation of respiration:
Learning objectives:
1. Describe the organisation of respiratory center
2. Describe the nervous control of inspiration and respiratory rhythm
3. Describe the functions of the dorsal and respiratory groups of neurons
4. Describe the influences of the Pneumotaxic and Apneustic centers
5. Explain the role of Hering-Breur inflation reflex in regulation of inspiration
6. Explain the role of central chemoreceptors in regulation of respiration
7. Explain the role of peripheral chemoreceptors in regulation of respiration
8. Explain the regulation of respiration during exercise
9. Integrate the respiratory regulatory mechanisms
10. Describe the Cheyne-Stokes breathing
Study Resources:
1. Chapter 42, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 36, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 13, Human Physiology by Lauralee Sherwood, 9th edition
“Psychiatry and the Humanities”: An Innovative Course at the University of Mo...
“Psychiatry and the Humanities”: An Innovative Course at the University of Mo...Université de Montréal
“Psychiatry and the Humanities”: An Innovative Course at the University of Montreal Expanding the medical model to embrace the humanities. Link: https://www.psychiatrictimes.com/view/-psychiatry-and-the-humanities-an-innovative-course-at-the-university-of-montreal5 Effective Homeopathic Medicines for Irregular Periods
Discover the benefits of homeopathic medicine for irregular periods with our guide on 5 common remedies. Learn how these natural treatments can help regulate menstrual cycles and improve overall menstrual health.
Visit Us: https://drdeepikashomeopathy.com/service/irregular-periods-treatment/
Full Handwritten notes of RA by Ayush Kumar M pharm - Al ameen college of pha...
Full Handwritten notes of RA by Ayush Kumar M pharm - Al ameen college of pha...ayushrajshrivastava7
Regulatory Affairs
Full hand written notes
M.pharm - 1st year .Recently uploaded (20)
June 2024 Oncology Cartoons By Dr Kanhu Charan Patro
June 2024 Oncology Cartoons By Dr Kanhu Charan Patro
Post-Menstrual Smell- When to Suspect Vaginitis.pptx
Post-Menstrual Smell- When to Suspect Vaginitis.pptx
Pune Call Girls 7339748667 AVAILABLE HOT GIRLS AUNTY BOOK NOW
Pune Call Girls 7339748667 AVAILABLE HOT GIRLS AUNTY BOOK NOW
acne vulgaris -Mpharm (2nd semester) Cosmetics and cosmeceuticals
acne vulgaris -Mpharm (2nd semester) Cosmetics and cosmeceuticals
Tele Optometry (kunj'sppt) / Basics of tele optometry.
Tele Optometry (kunj'sppt) / Basics of tele optometry.
Osvaldo Bernardo Muchanga-GASTROINTESTINAL INFECTIONS AND GASTRITIS-2024.pdf
Osvaldo Bernardo Muchanga-GASTROINTESTINAL INFECTIONS AND GASTRITIS-2024.pdf
The Nervous and Chemical Regulation of Respiration
The Nervous and Chemical Regulation of Respiration
“Psychiatry and the Humanities”: An Innovative Course at the University of Mo...
“Psychiatry and the Humanities”: An Innovative Course at the University of Mo...
5 Effective Homeopathic Medicines for Irregular Periods
5 Effective Homeopathic Medicines for Irregular Periods
Full Handwritten notes of RA by Ayush Kumar M pharm - Al ameen college of pha...
Full Handwritten notes of RA by Ayush Kumar M pharm - Al ameen college of pha...
Summary Presentation based on healthcare white paper by grail research
- 1. SUMMARY OF WHITE PAPER BY GRAIL RESEARCH APRAJAY MINOCHA MBA Marketing from JIIT
- 2. The “rule book” for success in healthcare had been relatively stable for several decades – new product innovation coupled with aggressive marketing However, the market is changing, pharmaceutical sales growth is down, fewer NMEs are being approved and media spending has seen significant cuts Recent deals between traditional healthcare players like Bayer, Merck, Dr. Reddy’s etc and new entrants like Costco, Nintendo, Fujifilm etc herald a fundamental shift in healthcare industry
- 3. Today, major healthcare players face “common threats” like patent expiration, generic threats, increasing role of payors in decision making and relatively uninspiring pipelines New trends, including the rising prominence of consumerism, information technology and the rising threat of Biosimilars are also being experienced. In combination, these factors are challenging the healthcare players to look outside the industry for ways to further innovate and remain competitive.
- 4. NEW TRENDS CONSUMERISM • 70 % of consumers seek health information on the internet • Many health-based website seeing double- digit growth in unique visitors HEALTHCARE IT • Heavy investment in Healthcare IT by governments of various countries. • Healthcare IT market expected to exceed $ 162 billion with a CAGR of 10.2 % BIOSIMILARS THREAT • Increasing threat of biosimilars due to expiring patents • The global financial crisis is increasing the pressure for healthcare systems to cut costs
- 6. Pfizer acquired Wyeth for $ 68 billion in 2009 Novartis acquired Alcon for $ 51.6 billion in 2011 Roche acquired Genentech for $ 46.8 billion in 2009
- 7. •Nintendo and Bayer Partnership •June 2009 •Developed Bayer’s DIDGET blood glucose monitoring system, which plugs into Nintendo DS. Targeted at diabetic kids. •Fujifilm’s acquisition of Sonosite •March 2012 •Sonsosite is a leader in bedside ultrasound, UHF micro-ultrasound technology & impedance cardiography equipment. •Samsung’s $ 300 million JV with Biogen Idec for biosimilars development. •Dec 2011 •85% JV owned by Samsung •Biogen will provide its expertise in protein engineering and biological manufacturing.
- 8. IMMEDIATE FACTORS Biosimilars Boom By 2015, sales of biosimilars expected to reach USD 1.9-2.6 billion, from $ 378 million in first half of 2011 Technology and Consumerism Consumer-friendly technologies Customer base and distribution channels
- 9. New Players Seek Growth • New players seek to tap the huge potential of healthcare industry, a $ 5.4 trillion market (7.7% of GDP). • New players can leverage their technology and expertise which is required to remain competitive in today’s healthcare market. • Example: Fujifilm’s JV with Dr Reddy’s will help to establish a strong presence in the Japanese pharmaceutical market Healthcare Players Seek Leverage • Existing healthcare players want to leverage others’ technology, manufacturing skills etc as they face cost constraints in the current economic market. • Example: Allscripts and Etransmedia’s partnership with Costco, provides them access to Costco’s customer base as a distribution channel.
- 10. Entry of new players in the healthcare industry, is a sign of changing healthcare landscape. In this changing landscape, the advantages of incumbency are offset by new challenges, and the non-healthcare focused companies now see a chance to enter an industry, which traditionally has been a closed one. The pace and magnitude of change in the healthcare industry has accelerated in the recent years. Companies are struggling to meet the demands for innovation and change. These demands come at a time when intense financial pressures are bogging down healthcare companies.
- 11. Many of these demands, in order to be fulfilled, require companies to participate in a market of products and services that is outside of their historical zone. The current trend of new players entering healthcare industry will continue, leading to a wide range of cross-industry collaborations and deals.